Following U.S. Food and Drug Administration review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer with K-RAS or EGFR-activated tumours. The Principal Investigator is Dr. Miguel Villalona-Calero, Professor Division of Hematology/Oncology and Department of Internal Medicine and Pharmacology at The Ohio State University Comprehensive Cancer Center.
“This trial gives Oncolytics the opportunity to treat NSCLC patients in a first-line clinical setting,” said Dr. Brad Thompson, President and CEO of Oncolytics. “Assuming we achieve an acceptable response rate, the combination of REOLYSIN with paclitaxel and carboplatin for NSCLC would be a strong candidate for registration studies.”
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of Phase 1/2 and Phase 2 human trials using REOLYSIN its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com
Filed under: News Wire | Tagged: Clinical Trials, Oncolytics Biotech, phase 2
